Drugs / TQB3456
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03754244 | Sep 2020 → Feb 2022 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3456 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03754244 ↗ |
| Route | Oral | “take TQB3456 p.o. qd” NCT03754244 ↗ |